Our most relevant clinical studies related to our smoke-free portfolio are shown below.

About consumer acceptance and the safety of our products


IDStudy titleStatus
NCT01967732Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)Completed
NCT01967706Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)Completed
NCT01959607Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)Completed
NCT01967719Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)Completed
NCT02466412Nicotine Pharmacokinetic Profile of the CHTP 1.1 MCompleted
NCT02643693User Acceptability of P3LCompleted
NCT02532374Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L Completed
NCT03369340
Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3PCompleted
NCT03379740
Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 VariantsCompleted

 

Measuring markers of harmful compounds in participants’ samples



IDStudy titleStatus
NCT01970982Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement SettingCompleted
NCT01959932Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.Completed
NCT01989156Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory SettingCompleted
NCT01970995Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory SettingCompleted
NCT02641587Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.Completed
NCT02503254Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.Completed
NCT03550989
Real-Life Passive Exposure Assessment of Platform 1Active, not recruiting

 

Collecting information about the risk of smoking-related diseases


IDStudy titleStatus
NCT02396381
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
Completed
NCT02649556A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2Completed
NCT02432729A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation (RIBESC)Completed


 

 

 

These trials are registered on www.clinicaltrials.gov, the most comprehensive clinical registry available today.

The size and duration of these studies vary considerably – from a few days in our pharmacokinetics studies, to up to one year in our Exposure Response Study where the goal is to observe near real-world product usage and favorable changes in risk markers linked to smoking related diseases. These studies are performed either in confinement, where participants are required to stay in the clinic, or in an ambulatory setting, where participants check-in at the clinic at regular intervals but otherwise live a normal life at home or at work. We also have studies that apply a combination of the two, starting with a short period in the clinic, followed by regular visits.

Our studies are conducted according to Good Clinical Practice and we also publish the results of our studies as they become available at www.clinicaltrials.gov and in peer-reviewed journals.

 

Read more on the International Conference of Harmonization’s Good Clinical Practice

 

Scientific Library

How does PMI conduct clinical trials

Long-Term Assessment

Long-Term Assessment

Our Network

We have a global network of research partners and our R&D facilities are located in Switzerland and Singapore.

Explore our network